Local Anesthetic Injections for the Short-Term Treatment of Head and Neck Myofascial Pain Syndrome: A Systematic Review with Meta-Analysis

Aims: To evaluate the effectiveness of local anesthetic trigger point injections in adults with myofascial pain syndrome (MPS) in the head, neck, and shoulder regions compared to dry needling, placebo, and other interventions. Methods: Randomized controlled trials using local anesthetic injections in adults diagnosed with MPS were included. The Cochrane Library, MEDLINE via PubMed, Web of Science, and EMBASE libraries were searched. The primary outcome was pain measured with a 0 to 10 visual analog scale (VAS). Secondary outcomes included pain threshold, range of cervical motion, depression scale, and pressure pain intensity (PPI) score. Risk of bias was analyzed based on Cochrane’s handbook. Results: The initial search strategy yielded 324 unduplicated references up to April 1, 2018. A total of 15 RCTs were included, with 884 adult patients diagnosed with MPS. Meta-analysis showed a significant improvement in VAS pain scale of 1.585 units at 1 to 4 weeks in the local anesthetic group compared to the dry needling group (95% confidence interval –2.926 to –.245; P = .020). However, when only including double-blinded studies, the effect was not statistically significant (P = .331). There was also a significant improvement in pain of 0.767 units with local anesthetic at 2 to 8 weeks compared to placebo (95% confidence interval –1.324 to –0.210; P = .007). No statistically significant differences were found in other secondary outcomes between local anesthetic and all other interventions. Conclusion: Though local anesthetics provided a significant improvement in pain compared to dry needling, evidence was of low quality, and sensitivity analyses including only double-blinded studies provided no statistically significant difference. Additional studies are needed to confirm these results.

dry needling;local anesthetic;meta-analysis;myofascial pain;myofascial trigger points;systematic review;visual analog scale

1. Jaeger B. Myofascial trigger point pain. Alpha Omegan 2013;106:14–22.

2. McMillan AS, Nolan A, Kelly PJ. The efficacy of dry needling and procaine in the treatment of myofascial pain in the jaw muscles. J Orofac Pain 1997;11:307–314.

3. Lugo LH, García HI, Rogers HL, Plata JA. Treatment of my- ofascial pain syndrome with lidocaine injection and physical therapy, alone or in combination: A single blind, randomized, controlled clinical trial. BMC Musculoskelet Disord 2016; 17:101.

4. Cerezo-Téllez E, Torres-Lacomba M, Fuentes-Gallardo I, et al. Effectiveness of dry needling for chronic nonspecific neck pain: A randomized, single-blinded, clinical trial. Pain 2016;157:1905–1917.

5. Erog˘ lu PK, Yilmaz O, Bodur H, Ates¸ C. A comparison of the ef- ficacy of dry needling, lidocaine injection, and oral flurbiprofen treatments in patients with myofascial pain syndrome: A dou- ble-blind (for injection, groups only), randomized clinical trial. Turk J Rheumatol 2013;28:38–46.

6. Celik D, Mutlu EK. Clinical implication of latent myofascial trig- ger point. Curr Pain Headache Rep 2013;17:353.

7. Majlesi J, Unalan H. Effect of treatment on trigger points. Curr Pain Headache Rep 2010;14:353–360.

8. Ustun N, Arslan F, Mansuroglu A, et al. Efficacy of EMLA cream phonophoresis comparison with ultrasound therapy on myofascial pain syndrome of the trapezius: A single-blind, ran- domized clinical study. Rheumatol Int 2014;34:453–457.

9. Venâncio Rde A, Alencar FG Jr, Zamperini C. Botulinum toxin, lidocaine, and dry-needling injections in patients with myofas- cial pain and headaches. Cranio 2009;27:46–53.

10. Manolopoulos L, Vlastarakos P V, Georgiou L, Giotakis I, Loizos A, Nikolopoulos TP. Myofascial pain syndromes in the maxillo- facial area: A common but underdiagnosed cause of head and neck pain. Int J Oral Maxillofac Surg 2008;37:975–984.

11. Royal MA. Botulinum toxins in pain management. Phys Med Rehabil Clin N Am 2003;14:805–820.

12. Graboski CL, Shaun Gray D, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind cross- over study. Pain 2005;118:170–175.

13. Romero-Reyes M, Uyanik JM. Orofacial pain management: Current perspectives. J Pain Res 2014;7:99–115.

14. Venâncio Rde A, Alencar FGP, Zamperini C. Different sub- stances and dry-needling injections in patients with myofascial pain and headaches. Cranio 2008;26:96–103.

15. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin in- jection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005;25:604–611.

16. Ay S, Evcik D, Tur BS. Comparison of injection methods in myofascial pain syndrome: A randomized controlled trial. Clin Rheumatol 2010;29:19–23.

17. Tschopp KP, Gysin C. Local injection therapy in 107 patients with myofascial pain syndrome of the head and neck. ORL J Otorhinolaryngol Relat Spec 1996;58:306–310.

18. Hong CZ. Lidocaine injection versus dry needling to myofas- cial trigger point. The importance of the local twitch response. Am J Phys Med Rehabil 1994;73:256–263.

19. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and me- ta-analyses: The PRISMA statement. PLoS Med 2009; 6:e1000097.

20. Simons DG, Travell JG, Simons LS, Cummings BD. Travell & Simons’ Myofascial Pain and Dysfunction. Volume 1: Upper Half of Body: The Trigger Point Manual, ed 2. Baltimore: Williams & Wilkins, 1999.

21. Travell J, Simons D. Myofascial Pain and Dysfunction: The Trigger Point Manual, ed 1. Baltimore: Williams & Wilkins, 1983.

22. Higgins J, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. Cochrane Collaboration, 2011.

23. Cochran W. The combination of estimates from different experiments. Biometrics 1954;10:101–129.

24. Higgins JP, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.

25. Cho IT, Cho YW, Kwak SG, Chang MC. Comparison be- tween ultrasound-guided interfascial pulsed radiofrequency and ultrasound-guided interfascial block with local anesthet- ic in myofascial pain syndrome of trapezius muscle. Medicine (Baltimore) 2017;96:e6019.

26. Choi JW, Lee CJ, Lee SM, Shin BS, Jun B, Sim WS. Effect of hyaluronidase addition to lidocaine for trigger point in- jection in myofascial pain syndrome. Pain Pract 2016; 16:1019–1026.

27. Iwama H, Akama Y. The superiority of water-diluted 0.25% to neat 1% lidocaine for trigger-point injections in myofascial pain syndrome: A prospective, randomized, double-blinded trial. Anesth Analg 2000;91:408–409.

28. Karadas¸ Ö, Gül HL, Inan LE. Lidocaine injection of pericranial myofascial trigger points in the treatment of frequent episodic tension-type headache. J Headache Pain 2013;14:44.

29. Sabatke S, Scola RH, Paiva ES, Kowacs PA. Injection of trig- ger points in the temporal muscles of patients with miofascial syndrome. Arq Neuropsiquiatr 2015;73:861–866.

30. Ga H, Koh HJ, Choi JH, Kim CH. Intramuscular and nerve root stimulation vs lidocaine injection to trigger points in myofascial pain syndrome. J Rehabil Med 2007;39:374–378.

31. Reeves JL, Jaeger B, Graff-Radford SB. Reliability of the pres- sure algometer as a measure of myofascial trigger point sensi- tivity. Pain 1986;24:313–321.

32. Fischer AA. Pressure algometry over normal muscles. Standard values, validity and reproducibility of pressure threshold. Pain 1987;30:115–126.

33. Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J 2001;18:205–207.

34. Fricton JR. Management of masticatory myofascial pain. Semin Orthod 1995;1:229–243.

35. Gerwin RD. Low back pain of muscular origin. In: Mense S, Gerwin R (ed). Muscle Pain: Diagnosis and Treatment. Berlin: Springer, 2010:161–192.

36. Liu L, Huang QM, Liu QG, et al. Effectiveness of dry needling for myofascial trigger points associated with neck and shoul- der pain: A systematic review and meta-analysis. Arch Phys Med Rehabil 2015;96:944–955.

37. McMilllan AS, Blasberg B. Pain-pressure threshold in painful jaw muscles following trigger point injection. J Orofac Pain 1994;8:384–390.

38. Scott NA, Guo B, Barton PM, Gerwin RD. Trigger point injec- tions for chronic non-malignant musculoskeletal pain: A sys- tematic review. Pain Med 2009;10:54–69.

39. Cummings M, Baldry P. Regional myofascial pain: Diagnosis and management. Best Pract Res Clin Rheumatol 2007; 21:367–387.

40. Gerwin RD. Myofascial trigger point pain syndromes. Semin Neurol 2016;36:469–473.

41. Ong J, Claydon LS. The effect of dry needling for myofascial trigger points in the neck and shoulders: A systematic review and meta-analysis. J Bodyw Mov Ther 2014;18:390–398.

42. Ho KY, Tan KH. Botulinum toxin A for myofascial trigger point injection: A qualitative systematic review. Eur J Pain 2007;11:519–527.

43. Kimura Y, Ge HY, Zhang Y, Kimura M, Sumikura H, Arendt- Nielsen L. Evaluation of sympathetic vasoconstrictor response following nociceptive stimulation of latent myofascial trigger points in humans. Acta Physiol (Oxf) 2009;196:411–417.

44. Vázquez-Delgado E, Cascos-Romero J, Gay-Escoda C. Myofascial pain associated to trigger points: A literature re- view. Part 2: Differential diagnosis and treatment. Med Oral Patol Oral Cir Bucal 2010;15:e639–e643.

45. Robbins MS, Kuruvilla D, Blumenfeld A, et al. Trigger point in- jections for headache disorders: Expert consensus methodol-ogy and narrative review. Headache 2014;54:1441–1459.